From January 30th to February 2nd, 2023, we will participate in the Arab Healthcare International Exhibition at the Dubai World Trade Center in the United Arab Emirates, 3 years after Corona in February 2020. There were quite a lot of company exhibition booths and visitors. Most do not wear masks. It's about to embarrass us wearing a mask.

First of all, a Saudi buyer who has been trading for 17 years received a proposal to activate the Saudi market for Anyfusion projects.

Saudi buyer requested to have our expert resident for 3-6 months, and they want the staff to provide product introduction and demo support to hospitals in the three major cities.

In addition, we have been working with them on progress since FDA STeP (monopoly only in the U.S., worldwide monopoly, patent transfer, etc. - Saudi Arabia demands monopoly rights from its own company), Lanching Ceremony inviting medical personnel to large hotels, 2-year warranty, 3-year paid A/S, prices, how-to videos, promises of large investment within 6 months, prompt consultations, and mutual visits by representatives of both companies within a short period of time.

The representative of Company L, introduced by UL, visited our booth and introduced Middle East partners. A Kuwaiti partner also visited the booth and discussed CE's quick certification request and demo regarding the Anyfusion ACPi system. (CEO of this company has high influence in Kuwait, etc.)

A large number of Indian buyers also visited the booth, and one of them consulted about the potential recognition of Anyfusin and its intention to invest.

We also discussed with a Hong Kong (ex-nurse) company, such as requesting exclusive negotiations with STeP and product strength.

Domestic: Confirmation of receipt of civil complaint application for treatment benefit (required benefit) for selective benefit to HIRA, assignment of person in charge, explanation of progress of internal procedures - Our product has been verified for safety and effectiveness with FDA STeP, and safety and effectiveness are reviewed as the top priority like life and the Ministry of Food and Drug Safety, we believe that the government no longer fulfills the role and function of the government by putting patients and medical staff at risk of medical accidents by using equipment whose safety and effectiveness are not guaranteed by selective reimbursement. Pharmaceuticals asked for regulatory and institutional improvements due to dereliction of duty.

Among the nine plans that FDA compared and reviewed, the use of devices with guaranteed prices was compared to the use of devices that were not guaranteed. STeP is presented as evidence that does not increase. Request for safe and highly effective medical service through rapid conversion.

FDA CDRH (Center for Devices and Radiological Health) Quality Management anf Organizational Exellence Program part and a video call for marketin intension of a company designated as STeP.

FDA-related departments that want to identify, complement, and develop the company's marketing intentions for items designated as STeP to vitalize the system and increase efficiency to maximize the system's functions request a video call directly and thank you for your efforts and efforts.

Thank you.